EasyM is our sensitive blood test using mass spectrometry to monitor minimal residual disease (MRD) for Multiple Myeloma. EasyM is CLIA approved for clinical use in the United States. Initial studies show high concordance with NGS based tests, predictive value for disease progression, and higher sensitivity than other methods.
EasyM is a non-invasive blood test for Multiple Myeloma disease monitoring (MRD). It uses a clonotypic mass spectrometry method and is much more sensitive than conventional assays. EasyM is currently available as a CLIA accredited lab test.